Low rate of severe venous thromboses in children with ALL treatment according to COALL-92 and-97 protocol

被引:10
作者
Mauz-Körholz, C [1 ]
Nürnberger, W [1 ]
Irsfeld, H [1 ]
Körholz, D [1 ]
Göbel, U [1 ]
机构
[1] Univ Dusseldorf, Klin Padiat Hamatol Onkol Med Einr, Med Ctr, Dept Pediat Haematol & Oncol, D-40225 Dusseldorf, Germany
来源
KLINISCHE PADIATRIE | 1999年 / 211卷 / 04期
关键词
acute lymphoblastic leukemia; venous thromboses; asparaginase; hereditary thrombophilia;
D O I
10.1055/s-2008-1043791
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Venous thromboses (VT) in children with ALL who were treated according to the COALL-89 protocol were reported to occur with a frequency of 2.1% (6/286). 4/6 of the reported VT were catheter related. However, in other cohorts of ALL patients treated according to American protocols the incidence of severe thromboses was 2-11%. Most of the VT were not catheter related, but were atypical thromboses like sinus venous thromboses. In these patients hereditary thrombophilia risk factors seemed to play a major role. In a 6 year period including the COALL protocols -92 and -97 only 10/684 (1.5%) children presented with symptomatic VT, and 7/10 thromboses were catheter related. Every thrombotic event could be successfully treated either by heparin administration or fibrinolytic agents. 2/10 VT were secondary due to a septic event. 5 out of 8 primary VT occurred after asparaginase/dexamethasone application during the reinduction therapy. In conclusion, symptomatic thrombotic events are very rare in the COALL studies. Important risk factors for development of VT appeared to be central lines, asparaginase application and infectious/septic complications. However, the role of genetic risk factors of thrombosis in these patients has still to be determined.
引用
收藏
页码:215 / 217
页数:3
相关论文
共 14 条
[1]   4-AGENT INDUCTION AND INTENSIVE ASPARAGINASE THERAPY FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
CLAVELL, LA ;
GELBER, RD ;
COHEN, HJ ;
HITCHCOCKBRYAN, S ;
CASSADY, JR ;
TARBELL, NJ ;
BLATTNER, SR ;
TANTRAVAHI, R ;
LEAVITT, P ;
SALLAN, SE .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (11) :657-663
[2]   THROMBOSES IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA TREATED WITH THE COALL-PROTOCOLL [J].
ECKHOFDONOVAN, S ;
SCHWAMBORN, D ;
KORHOLZ, D ;
MICHELMANN, I ;
VONKRIES, R ;
NURNBERGER, W ;
GOBEL, U .
KLINISCHE PADIATRIE, 1994, 206 (04) :327-330
[3]   L-ASPARAGINASE - THERAPEUTIC AND TOXIC EFFECTS IN PATIENTS WITH NEOPLASTIC DISEASE [J].
HASKELL, CM ;
CANELLOS, GP ;
LEVENTHAL, BG ;
CARBONE, PP ;
BLOCK, JB ;
SERPICK, AA ;
SELAWRY, OS .
NEW ENGLAND JOURNAL OF MEDICINE, 1969, 281 (19) :1028-+
[4]  
JankaSchaub GE, 1996, EUR J PEDIATR, V155, P640
[5]   Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05-92-protocol [J].
Kirschke, R ;
Nurnberger, W ;
Eckhof-Donovan, S ;
Nurnberger, I ;
Gobel, U .
KLINISCHE PADIATRIE, 1998, 210 (04) :285-290
[6]  
MITCHELL L, 1994, BLOOD, V83, P386
[7]   HEMOSTASIS IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA - COAGULOPATHY INDUCED BY DISEASE AND TREATMENT [J].
MITCHELL, LG ;
SUTOR, AH ;
ANDREW, M .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1995, 21 (04) :390-401
[8]   Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors [J].
Nowak-Göttl, U ;
Wermes, C ;
Junker, R ;
Koch, HG ;
Schobess, R ;
Fleischhack, G ;
Schwabe, D ;
Ehrenforth, S .
BLOOD, 1999, 93 (05) :1595-1599
[9]   Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism [J].
NowakGottl, U ;
Koch, HG ;
Aschka, I ;
Kohlhase, B ;
Vielhaber, H ;
Kurlemann, G ;
OleszcukRaschke, K ;
Kehl, HG ;
Jurgens, H ;
Schneppenheim, R .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) :992-998
[10]  
OTT N, 1988, AM J PEDIAT HEMATOL, V10, P191